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Importance: Difficult-to-heal wounds pose clinical and economic challenges, and cost-effective 
treatment options are needed.
Objective: The aim of this study is to determine the cost-effectiveness of extracellular matrix 
(ECM) relative to standard of care (SC) on wound closure for the treatment of mixed arterial/
venous (A/V) or venous leg ulcers (VLUs).
Design, setting, and participants: A two-stage Markov model was used to predict the expected 
costs and outcomes of wound closure for ECM and SC. Outcome data used in the analysis were 
taken from an 8-week randomized clinical trial that directly compared ECM and SC. Patients were 
followed up for an additional 6 months to assess wound closure. Forty-eight patients completed 
the study; 25 for ECM and 23 for SC. SC was defined as a standard moist wound dressing. 
Transition probabilities for the Markov states were estimated from the clinical trial.
Main outcomes and measures: The economic outcome of interest was direct cost per closed-
wound week. Resource utilization was based on the treatment regimen used in the clinical trial. 
Costs were derived from standard cost references. The payer’s perspective was taken.
Results: ECM-treated wounds closed, on average, after 5.4 weeks of treatment, compared with 
8.3 weeks for SC wounds (P=0.02). Furthermore, complete wound closure was significantly 
higher in patients treated with ECM (P,0.05), with 20 wounds closed in the ECM group (80%) 
and 15 wounds closed in the SC group (65%). After 8 months, patients treated with ECM had 
substantially higher closed-wound weeks compared with SC (26.0 weeks versus 22.0 weeks, 
respectively). Expected direct costs per patient were $2,527 for ECM and $2,540 for SC (a cost 
savings of $13).
Conclusion and relevance: ECM yielded better clinical outcomes at a slightly lower cost 
in patients with mixed A/V and VLUs. ECM is an effective treatment for wound healing and 
should be considered for use in the management of mixed A/V and VLUs.
Keywords: extracellular matrix, adjunct therapy, venous leg ulcers, wound care, compression 
therapy, economic outcomes
Introduction
Difficult-to-heal chronic wounds often require care for several months. Even when good 
wound care practices are used, healing rates remain low. Venous leg ulcers (VLUs) 
require an average of 24 weeks to heal; however, approximately 15% of VLUs never 
heal, and recurrence is common (15%–71%).1,2 For mixed arterial/venous (A/V) ulcers, 
healing rates vary from 23% to 64% for ulcers associated with severe and moderate 
arterial disease, respectively.3 Low healing rates in VLUs and mixed A/V ulcers indi-
cate that current standard of care (SC) is often inadequate. New strategies should be 
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considered as alternatives to standard care (compression 
therapy, debridement, and maintenance of a moist wound 
environment).4
Initial healing rate of VLUs and percentage change in ulcer 
area after treatment initiation predict ulcer healing.5 A VLU 
treatment algorithm suggests that .40% wound  closure after 
4 weeks of conventional therapy is an appropriate surrogate 
marker to identify patients likely to achieve complete wound 
closure with SC.6 It is unlikely that patients with ,40% 
closure after 4 weeks of conventional therapy will have 
complete wound healing and could benefit from alternative 
or advanced interventions.7 Chronic wounds do not typically 
follow proper wound healing process (hemostasis, inflam-
mation, proliferation, and remodeling phases8) and often 
become stalled in the inflammation or proliferation states.9 
Chronic wounds cannot re-epithelialize owing to failure of 
keratinocyte migration rather than proliferation.10 Failure of 
migration may occur from lack of a functional extracellular 
matrix (ECM), where there may be deficiencies in fibronectin 
and collagen molecules.11–14 High concentrations of ECM-
degrading proteases, misregulated rates of matrix repair and 
degradation, increased numbers of senescent fibroblasts, or 
altered cytokine expression and redistribution may impede 
ECM function in chronic wounds.15–19 Lack of a functional 
ECM could inhibit normal wound repair process.
Alternative avenues have explored advanced therapies 
using cellular/tissue-derived products (CTPs), such as 
ECM.20 ECM wound matrix is derived from a thin, translu-
cent tunica submucosa layer of porcine small intestine. Once 
harvested, all living cells are removed from the biomate-
rial and it is sterilized and lyophilized to allow long-term 
storage.21,22 The low porosity value of ECM indicates that it 
may be an effective barrier to wound bed dehydration.23–25 
In vitro data indicate that ECM wound matrix provides an 
environment that allows proper fibroblast and keratinocyte 
cell attachment, proliferation, and migration.26,27 ECM is 
fixed to wounds and is typically reapplied every 3–7 days 
until closure.28,29 The efficacy of ECM in the management of 
VLUs, mixed A/V ulcers, and diabetic foot ulcers has been 
established.20,30–33 Data suggest that difficult-to-heal chronic 
wounds benefit from natural ECM wound matrix replace-
ment therapy, as it promotes angiogenesis, cellular growth, 
and wound closure.
Difficult-to-heal wounds pose clinical and economic chal-
lenges.34 Estimated annual payer burden of VLUs approached 
$15 billion as of 2014.35 Relative to non-VLU patients, VLU 
patients incurred additional annual incremental costs of 
$6,391 through Medicare, while those with private insurance 
incurred additional costs of $7,030.35 VLUs account for the 
loss of .2 million workdays/year.36 The primary objective 
of this study was to assess the cost-effectiveness of single-
layer ECM (OASIS Wound Matrix®; Cook Biotech Inc., West 
Lafayette, IN, USA) as an adjunct therapy to SC compared 
with SC alone on wound closure for the treatment of VLUs 
and mixed A/V ulcers.
Methods
Study participants, design, and interventions
Data were derived from an 8-week randomized clinical trial 
of adults aged $18 years with VLU or mixed A/V ulcer 
(determined by clinical/instrumental assessment).37 Fifty 
patients with lower leg ulcers of mixed A/V (n=23) and 
venous (n=27) etiology visiting the outpatient leg ulcer clinic 
at the Wound Healing Research Unit, Department of Derma-
tology, University of Pisa, Italy, were prospectively selected 
for enrollment into a randomized trial that was approved by 
the institutional review board and local ethics committee 
of the Azienda Ospedaliera Universitaria Pisana.37 Patients 
were required to provide written informed consent before the 
clinical trial. Eligible patients had VLU or mixed A/V leg 
ulcer with an ankle brachial index of 0.6–0.8, ulcer duration 
of .6 months, ulcer size .2.5 cm2, and 50% granulation 
tissue on the wound bed.37
Patients who met the inclusion/exclusion criteria were 
randomized to treatment with ECM (n=25) or with standard 
moist wound dressing (petrolatum-impregnated gauze; n=25) 
after written informed consent was received. ECM material 
was cut to a size slightly larger than the wound, positioned 
directly on the wound, and moistened with saline; a secondary 
nonadherent dressing was applied. In the SC group, ulcers 
were treated with petrolatum-impregnated gauze applied with 
a secondary nonadherent dressing.
Wound closure and dressing were assessed at baseline 
and weekly for up to 8 weeks. Time to complete healing, 
percentage of granulation tissue (assessed by validated color 
defragmentation software), 38 signs of infection, surrounding 
skin aspect, and comfort at dressing change were measured 
by clinical assessment and digital planimetry and assessed 
weekly. To ensure patients were blinded, they were instructed 
to change only the secondary dressing at home and were 
evaluated twice a week in the clinic, where the investigators 
performed all clinical and instrumental evaluations. Patients 
were followed monthly for 32 weeks to assess wound closure 
after the conclusion of the trial.
Economic analysis
Markov models are designed to aid health care decision 
 makers in clinical situations for events (ie, health states) 
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and to measure the burden of illness of specific health states 
as they transition over time. The patients are considered to 
be in one of a finite number of discrete health states that 
 incorporate all clinically important events into transition 
probabilities from one health state to another. A Markov 
model (TreeAge Pro Version 2014; TreeAge Software, Inc., 
Williamstown, MA, USA) was developed to compare the 
clinical outcomes and costs of ECM versus SC using the 
wound closure rates to estimate the number of closed-wound 
weeks and the expected VLU and mixed A/V ulcer cost per 
patient. Outputs from the Markov model were then used to 
derive a cost-effectiveness ratio for each treatment group, 
defined as the expected cost per closed-wound week. Using 
this approach, results were derived over 32 weeks to estimate 
the number of closed-wound weeks per treatment arm, in 
addition to the average cost to achieve closure (primary 
clinical outcome).
Resource utilization was based on the average time to 
dressing change reported in the trial. Costs were derived from 
standard cost references and medical supply wholesalers in 
the USA. The number of ECM applications was based on the 
treatment regimen used in the trial. A sensitivity analysis was 
performed on all costs associated with treatment to test the 
robustness of the model’s assumptions (ie, variables selected 
for model input) on the results.
Model inputs
Time horizon
A 32-week time horizon was selected to model the total costs 
across the entire episode of care for both treatment groups 
for the length of the trial (including follow-up assessments). 
Costs associated with outpatient treatment accrued until 
wound closure.
Two-state Markov model and transition probabilities
A two-state Markov model was a cycle length of 1 week and 
was chosen to follow the closed (epithelialized) and unhealed 
stages of VLU and mixed A/V ulcers (Figure 1). State 1, the 
unhealed state, represents healing VLUs and mixed A/V 
ulcers and, consequently, the total costs associated with 
treatment in the outpatient setting (ie, clinic visits, applica-
tion of a skin substitute product, and facility and physician 
reimbursement). State 2, the closed phase, represents a 
closed VLU or mixed A/V ulcer and, consequently, incurs 
no additional costs. The transition probabilities from the 
unhealed to the closed phase were determined using wound 
closure rates from the randomized clinical trial.37 At the end 
of 8 weeks, approximately 80% of patients in the ECM group 
were considered closed compared with 65% in the SC group. 
These probabilities were extrapolated through the follow-up 
phase of 32 weeks, assuming cumulative probability rates 
over time using equations described by Briggs et al.39–41 This 
time-dependent Markov model provides a robust method to 
modeling a chronic disease state, since the assumption of 
constant transition probabilities is considered too restric-
tive for applications in health care.41 These weekly transi-
tion rates were used to populate the Markov model and to 
analyze clinical and economic outcomes. No adverse events 
were observed with either treatment; therefore, additional 
complications such as infection were not considered in the 
Markov analysis. Furthermore, due to the short duration of 
the trial, recurrence was not measured.
Clinical outcomes definition
The clinical outcome for the Markov model was defined as 
“closed-wound weeks” and represents the expected number 
of weeks that the wound was closed over the 32-week trial. 
Complete healing in VLU and mixed A/V ulcer was defined 
as growth of epithelium over a denuded surface without evi-
dence of bleeding or drainage.42 These results are presented 
as closed-wound weeks to effectively demonstrate the dif-
ferences in the wound healing trajectories between the two 
treatment groups. Closed-wound weeks represent the average 
expected time, in weeks, that VLU and mixed A/V ulcers 
remain closed in the two comparative cohorts given their 
respective transition probabilities from the unhealed state 
to the healed state. Closed-wound weeks are a mathematical 
complement to open-wound weeks and represent a positive 
measure of clinical outcomes.
Economics outcomes definition
The analysis was from the perspective of the third-party 
payer, and only direct medical costs of care were  considered. 
Costs were reported in 2015 US dollars. Because of the 
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Figure 1 Weeks to healing across treatment groups.
Notes: A Student’s t-test was used to compare outcomes.
Abbreviations: ECM, extracellular matrix; SC, standard of care.
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short duration of the model, costs were not discounted. 
A cost-effectiveness analysis was performed assessing cost 
per closed-wound week on a per-patient basis. Derivation 
of costs is displayed in Table 1. Given the 2014 changes 
to the Hospital Outpatient Prospective Payment System 
rates,31 ECM was considered a low-cost skin substitute.31 
New Hospital Outpatient Prospective Payment System rates 
represent a bundled payment of facility reimbursement and 
product cost. Costs for low-cost skin substitutes, physician 
reimbursement for application of a skin substitute, facility 
reimbursement for an outpatient established clinic visit, and 
physician evaluation and management visits were used per 
the results of the trial. The ECM-treated group required fewer 
dressing changes, more than doubling the number of days 
between dressing changes compared with the SC-treated 
group (2.1 versus 5.2, respectively; P,0.05). Therefore, unit 
costs for ECM-treated ulcers were calculated at 1 visit/wk 
and SC-treated ulcers at 3 visits/wk.
Sensitivity analyses
Sensitivity analysis consists of change in the value of an 
input parameter to assess the magnitude of its effect on the 
final results of the analysis (ie, change in total cost of care 
and change in rates of healing). One-way sensitivity analyses 
test the robustness of the model’s assumptions on the results 
(ie, variables selected for model input). Deterministic sen-
sitivity analysis assists with justification for the choice of 
variables included in the model, in addition to providing an 
explanation for the source of ranges used. Variables with 
uncertainty (ie, costs and healing rates) or expectation of sen-
sitivity were selected for these analyses. Sensitivity analyses 
were conducted on the probability of healing for ECM and 
SC, the costs for the bundled facility and product payment, 
and the physician reimbursement. Due to the uncertainty that 
surrounds VLUs of various sizes and shapes43 in addition to 
varying costs of reimbursement per geographic region in the 
USA, a ±50% variance around the base case estimated were 
utilized to incorporate the varying rates of healing and costs 
to assess the robustness of the model’s results.
Probabilistic sensitivity analysis was performed to evalu-
ate parameter uncertainty by using a second-order Monte 
Carlo simulation of 10,000 trials; all model inputs were varied 
simultaneously. The cost-effectiveness ratio was recalculated 
from the dummy data set; the process was repeated multiple 
times (ie, 10,000). Beta and gamma distributions were applied 
for transition probabilities and assessing variance in total cost 
of care, respectively.
Results
Of the 50 patients who enrolled, 48 completed the study (two 
discontinued due to relocation). There were 25 and 23 patients 
in the ECM-treated and SC-treated groups, respectively. 
No significant differences were observed between the two 
groups with respect to demographics and ulcer and duration 
(Table 2). Average wound surface was 23.5 cm2 for ECM and 
25.2 cm2 for SC. Before initiation of treatment, the average 
wound age was 7.2 weeks for the ECM group and 6.9 weeks 
for the SC group.
After 8 weeks, ECM-treated wounds healed in 5.4 weeks 
(mean) compared with 8.3 in the SC group (Figure 1).  Complete 
wound closure occurred in 80% (n=20) and 65% (n=15) of the 
ECM-treated and SC-treated wounds, respectively. For wounds 
that did not close within 8 weeks, granulation tissue in the 
wound bed increased 30% (from 50% at baseline to 65% at 
8 weeks) in the ECM-treated group and decreased 24% (from 
50% at baseline to 38% at 8 weeks) in the SC-treated group 
(P,0.05). No adverse events occurred with either treatment. 
Projected closure rates were greater for the ECM group com-
pared with SC group (98% versus 91%, respectively).
Economic results
The primary clinical outcome for this economic analysis was 
closed-wound weeks. On the basis of the transition rate of the Table 1 Unit cost
Resource Quantity Cost
HOPPS rate low cost skin substitute  
(C5271)a
1 visit/wk $430.12
Physician rate skin substitute  
application (CPT 15271)
1 visit/wk $87.24
OPPS rate hospital outpatient clinic 
visit (G0463)a
3 visits/wk $294.18
Physician rate evaluation and  
management visit level 2 (CPT 99212)
3 visits/wk $77.34
Note: aHealthcare Common Procedure Coding System (HCPCS) stated.
Abbreviations: CPT, Current Procedural Terminology; HOPPS, Hospital 
Outpatient Prospective Payment System; OPPS, Outpatient Prospective Payment 
System; wk, week.
Table 2 Population demographics
Variable ECM (n=25) SC (n=23) P-value
Male, % 52 48 NSS
Ulcer size, mean, cm2 23.5 25.2 NSS
Ulcer duration, mean, wk 7.2 6.9 NSS
Note: Data were analyzed using Analysis of Variance (ANOVA) for multiple 
comparisons (SPSS 10 for Windows), with the significance level set at P,0.05. 
Additionally, Male %  significance was tested  via a chi-square and Ulcer size and 
Ulcer duration were tested via a student’s t-test.
Abbreviations: ECM, extracellular matrix; NSS, not statistically significant; SC, 
standard of care; wk, week.
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prospective  clinical trial data, the expected number of closed-
wound weeks accumulated over 32 weeks was higher for the 
ECM-treated arm (26.0 weeks for ECM versus 22.0 weeks for 
SC, respectively) (Figure 2). To provide another perspective, 
the clinical complement to closed-wound weeks is open-wound 
weeks. Consequently, the expected number of open-wound 
weeks for the ECM and SC cohorts was estimated at 6.0 weeks 
and 10.0 weeks, respectively. It is important to note that there 
is a 4-week difference (∼1 month) in wound closure between 
ECM and SC. Patients receiving the SC treatment would have, 
on average, four additional open-wound weeks compared with 
patients treated with ECM wound matrix. These results indicate 
that ECM is more clinically effective than SC alone for the man-
agement of difficult-to-heal VLUs and mixed A/V ulcers.
Expected costs per ulcer at the end of the 32-week phase 
were $2,527 and $2,540 for the ECM and SC groups, respec-
tively, which equates to a cost savings of $13 for the ECM-
treated group. Therefore, ECM was economically dominant, 
providing better clinical outcomes at a slightly lower cost 
compared with SC. The incremental cost-effectiveness 
ratio (ICER) for ECM was $−3.75, indicating that for each 
$−3.75 paid for ECM therapy, patients gained 1 closed-wound 
week. While differences in these costs are not substantially 
different, it is important to note that the clinical benefit of 
ECM surpasses that of SC by providing, on average, an 
additional month of wound closure.
Sensitivity analyses
One-way deterministic sensitivity analysis revealed no 
thresholds where the primary findings changed. The most 
influential variables were the Outpatient Prospective  Payment 
System reimbursement for a hospital outpatient clinic 
visit, the probability of healing on SC weeks 1–8, and the 
 physician reimbursement for evaluation and management 
visits. All model inputs were considered in the sensitivity 
analysis. The values of these inputs were derived from CPT 
and Healthcare Common Procedure Coding System codes 
for 2015 Medicare-allowable total expected costs. When 
visits per week in the SC group were varied to two visits, 
ECM-treated ulcers still provided greater clinical outcomes 
but at a slightly higher cost ($2,527 for ECM and $1,885 for 
SC-treated ulcers).
Probabilistic sensitivity analysis indicated that adjunct 
ECM had the highest average effectiveness of 26±1.2 closed-
wound weeks, whereas SC had the lowest at 22±1.4 closed-
wound weeks. The cost-effectiveness acceptability curve 
(Figure 3) illustrates the probability that any one strategy 
is cost-effective as a function of willingness to pay. Given a 
maximum acceptable ceiling ratio of $2,000/closed-wound 
week, the probability that ECM is cost-effective compared 
with SC is 95%. If a patient’s willingness to pay is $0, the 
probability that ECM is cost-effective compared with SC 
is 53%.
Discussion
ECM as adjunct therapy to SC provided greater clinical 
benefit at a marginally lower cost than SC over 32 weeks. 
Patients treated with ECM would pay no additional cost per 
week to gain 1 additional closed-wound week compared with 
SC alone. Hospital outpatient department visits for facility 
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Figure 2 Comparison of closed-wound weeks between a cellular/tissue-derived product treatment in relation to SC for the management of venous leg ulcers. 
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and physician in addition to the probability of healing on SC 
for weeks 1–8 exerted the greatest influence on expected total 
costs for VLU. This Markov model provided a robust method 
to model a chronic disease state, since the assumption of 
constant transition probabilities is considered too restrictive 
for applications in health care.41 When the ECM adjunct 
therapy was compared with SC alone, ECM provided higher 
clinical benefit at a marginally lower cost. The SC treatment 
arm had 10 open-wound weeks (mean) relative to the ECM 
treatment arm (6 weeks). The longer a wound remains in the 
unhealed health state, the greater the risk of infection, risk 
of amputation, additional costs of care for clinic and product 
visits, and decreased quality of life.1,44–46 If an individual is 
willing to pay no additional cost per closed-wound week, the 
likelihood that ECM is cost-effective is ∼53% relative to SC. 
However, if an individual is willing to pay an additional $300 
per additional closed-wound week, then the likelihood that 
ECM is cost-effective increases to 85%, respectively. Given 
the low success rates of closure using SC, ECM could be 
considered a cost-effective alternative to SC alone for the 
management of VLUs.
Modeling direct costs of wound care therapy in conjunc-
tion with healing trajectories can be challenging. Further-
more, there is a lack of rigorous investigations examining 
the economic burden of treatments for the management of 
VLUs. Carter et al found that ECM provided similar  clinical 
outcomes at a substantially lower cost than other CTPs 
(∼$3,900 less compared with human skin equivalent and 
$4,500 less relative to living skin equivalent).47 Relative to 
SC, ECM costs an additional $600 annually, but provided 
seven additional closed-wound weeks.47 Similar results were 
found in a study by Hankin et al who evaluated the clinical 
and economic efficacy of ECM, human skin equivalent, and 
Talymed as an adjunct to SC compared with SC alone for the 
treatment of chronic VLUs and found ICERs per addition-
ally successfully treated patient were $1,600 for Talymed, 
$3,150 for ECM, and $29,952 for human skin equivalent 
after 24 weeks.48 Results from this study for ECM at 32 weeks 
(∼$2,527) are consistent with findings from both studies. In 
diabetic foot ulcers, ECM yielded similar clinical outcomes 
to human skin equivalent but at a significantly lower cost 
($2,522 versus $3,889 over 12 weeks, respectively; 2015 US 
dollars).49 Previous cost-effectiveness analyses have found 
similar results when assessing the relative costs and benefits 
of CTPs in the management of VLUs. Schonfeld et al evalu-
ated the cost-benefit of human skin equivalent in comparison 
to Unna’s boot as the SC using a semi-Markov model over 
a 1-year time horizon and found that rates of healing in the 
human skin equivalent group were ∼48.1% compared with 
25.2% in SC patients. Annual costs for human skin equivalent 
were slightly more expensive than the annual cost for Unna’s 
boot patients ($12,807 versus $10,482, respectively; 1996 
US dollars), with a calculated ICER of $800 per additional 
month of healing.50 Similar results comparing human skin 
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equivalent to SC have been found in other studies in the UK 
and Canada with human skin equivalent providing a higher 
clinical benefit at a slightly higher cost.51,52
Closure rates in ECM-treated VLUs reported in the 
clinical trial used for this economic analysis are higher 
than those previously reported. A randomized clinical trial 
with 120 patients with chronic leg ulcers reported 55% of 
ECM-treated chronic ulcers closed after 12 weeks of treat-
ment.20 Interim analysis of another clinical trial reported 
similar  closure rates (71% of ECM-treated VLUs closed 
at 12 weeks).53 The majority of wounds in both studies 
ranged from 1 month to 1 year.20,53 A greater percentage of 
closed patients in this study might reflect that wounds were 
treated earlier in the progression from a slow-to-heal wound 
to a difficult-to-heal wound, as the majority of VLUs and 
mixed A/V ulcers in this trial were 6–7 weeks old.
Management of VLUs and mixed A/V ulcers remains 
challenging. The overall burden of illness for VLU com-
prises 2% of health care expenditures for Western European 
countries and almost $15 billion annually in the USA.35,54–57 
Distinct differences exist across countries in resource 
 utilization, regarding treatment algorithms for VLUs.57 The 
majority of expenditures for Medicare patients were com-
prised of outpatient/physician and emergency department 
visits, whereas costs for hospitalizations and outpatient/
physician office visits were highest among those with private 
 insurance.35 Hospitalization was the primary cost driver for 
VLUs in Germany, whereas drugs and office nurse visits were 
 primary drivers in the USA. Despite differences in health care 
provider practice patterns and resource utilization, health 
care expenditures and rates of closure for VLUs are similar 
between countries.55 Comparing costs between the UK and 
Sweden, total costs of care for chronic wounds were gener-
ally higher in Sweden.56 Although CTPs are rarely used in 
Europe, similar costs and outcomes support the argument 
that conventional treatment practices may be supplemented 
by other options, such as CTPs, in an attempt to overcome 
the pathophysiological challenges of difficult-to-heal chronic 
wounds. In the Netherlands, two treatment modalities exist 
for VLUs: conservative treatment (eg, compression therapy, 
local treatment, and leg elevation) and surgical treatment (eg, 
superficial and perforating vein ablation and deep vein recon-
struction).54 Due to restricted access to advanced therapies, 
health care providers in the Netherlands suggest that surgery 
plus compression therapy is an effective treatment modality 
for VLU, which could escalate costs.54
Certain limitations should be considered when inter-
preting these results. Data were derived from a clinical trial 
conducted at one outpatient leg clinic with a small patient 
sample; results are not generalizable to other SC methods, 
health care settings, or wounds types. Although study investi-
gators were trained in a uniform manner to ensure consistent 
treatment application and techniques, performance bias is 
still possible. While patients were blinded to the treatment 
administered, this study was not double blinded; therefore, 
observation bias is possible. Ulcer recurrence was not cap-
tured in this model because it was not assessed in the clinical 
trial. Finally, while this trial was conducted outside the USA, 
the model was based on US physician practice patterns. 
Centers for Medicare and Medicaid Services recommends 
that usual dressing change for gauze dressings impregnated 
with other than water, normal saline, hydrogel, or zinc paste 
be changed up to once per day,58 thereby resulting in multiple 
potential weekly clinic visits if patients are unable to change 
their own dressing.
Conclusion
Advanced therapeutic intervention is often required for 
difficult-to-heal wounds, which frequently have dysfunc-
tional ECM. ECM adjunct therapy provided more closed-
wound weeks at a slightly lower cost of care compared with 
SC in the management of VLUs and mixed A/V ulcers. 
Depending on an individual’s willingness to pay, ECM 
can be considered a cost-effective alternative to SC alone 
for the management of VLUs. Earlier treatment of VLUs 
and mixed A/V ulcers with CTPs, although initially more 
expensive, may be more efficacious and less costly in the 
long term by preventing recurrence, infection, or hospi-
talization. Wound care treatment algorithms and practice 
patterns should be reviewed and updated to reflect findings 
from current research.
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